Adverse event data · women undergoing assisted reproduction
1 finding from 1 review
Adverse events (haemodynamic instability) · acute ischaemic stroke endovascular treatment (long‐term)
General anaesthesia may leads to lower adverse events (haemodynamic instability) compared with non‐general anaesthesia (low certainty).
1 finding from 1 review
Adverse events due to periodontal therapy · Patients with cardiovascular disease and chronic periodontitis
1 finding from 1 review
Adverse events: because of variable follow-up (6 to 25 months) and almost 90% loss to follow-up by one year, results were not considered useful for analysis; uncertain whether adverse events are more likely with either…
1 study · 303 participants
GRADE not reported
Adverse event: lead failure/ displacement · adults with chronic pain
It is very uncertain whether active stimulation + other intervention changes adverse events:lead failure/ displacement compared with other intervention alone (very low certainty).
2 findings from 1 review
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment cessation due to adverse events · CRRT
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
1 finding from 1 review
Fatal or non‐fatal serious adverse events · people with primary hypertension
Renin inhibitors showed no clear difference in fatal or non‐fatal serious adverse events compared with ACE inhibitors (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (number of people) · people with liver cirrhosis and ascites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: persistent nephrotoxicity · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Post‐operative atelectasis · participants with β‐thalassaemia
It is very uncertain whether the intervention changes adverse events Post‐operative atelectasis (very low certainty).
1 finding from 1 review
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Intervention not reported
Adverse events 12 months postintervention · adults with refractory glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Grade 3 to 4 neutropenia · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review